These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 33974881)

  • 1. New generation ENaC inhibitors detach cystic fibrosis airway mucus bundles via sodium/hydrogen exchanger inhibition.
    Giorgetti M; Klymiuk N; Bähr A; Hemmerling M; Jinton L; Tarran R; Malmgren A; Åstrand A; Hansson GC; Ermund A
    Eur J Pharmacol; 2021 Aug; 904():174123. PubMed ID: 33974881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
    Moore PJ; Tarran R
    Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.
    Shei RJ; Peabody JE; Kaza N; Rowe SM
    Curr Opin Pharmacol; 2018 Dec; 43():152-165. PubMed ID: 30340955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport.
    Scott DW; Walker MP; Sesma J; Wu B; Stuhlmiller TJ; Sabater JR; Abraham WM; Crowder TM; Christensen DJ; Tarran R
    Am J Respir Crit Care Med; 2017 Sep; 196(6):734-744. PubMed ID: 28481660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of the epithelial sodium channel inhibitor AZD5634 and implications on human translation.
    Åstrand A; Libby EF; Shei RJ; Lever JEP; Kaza N; Adewale AT; Boitet E; Edwards L; Hemmerling M; Root J; Lindberg B; Wingren C; Malmgren A; Sabater J; Rowe SM
    Am J Physiol Lung Cell Mol Physiol; 2022 Nov; 323(5):L536-L547. PubMed ID: 36098422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells.
    Mroz MS; Harvey BJ
    Steroids; 2019 Nov; 151():108461. PubMed ID: 31344409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art.
    Althaus M
    Curr Mol Pharmacol; 2013 Mar; 6(1):3-12. PubMed ID: 23547930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CFTR and ENaC debate: how important is ENaC in CF lung disease?
    Collawn JF; Lazrak A; Bebok Z; Matalon S
    Am J Physiol Lung Cell Mol Physiol; 2012 Jun; 302(11):L1141-6. PubMed ID: 22492740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does epithelial sodium channel hyperactivity contribute to cystic fibrosis lung disease?
    Hobbs CA; Da Tan C; Tarran R
    J Physiol; 2013 Sep; 591(18):4377-87. PubMed ID: 23878362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ENaC as a Molecular Suspect in Cystic Fibrosis.
    Bangel-Ruland N; Tomczak K; Weber WM
    Curr Drug Targets; 2015; 16(9):951-7. PubMed ID: 25544019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transport properties in CFTR-/- knockout piglets suggest normal airway surface liquid pH and enhanced amiloride-sensitive Na
    Benedetto R; Centeio R; Ousingsawat J; Schreiber R; Janda M; Kunzelmann K
    Pflugers Arch; 2020 Oct; 472(10):1507-1519. PubMed ID: 32712714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.
    Ermund A; Meiss LN; Gustafsson JK; Hansson GC
    Eur J Pharmacol; 2015 Oct; 764():109-117. PubMed ID: 26134505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cAMP triggers Na
    Luan X; Le Y; Jagadeeshan S; Murray B; Carmalt JL; Duke T; Beazley S; Fujiyama M; Swekla K; Gray B; Burmester M; Campanucci VA; Shipley A; Machen TE; Tam JS; Ianowski JP
    Cell Rep; 2021 Oct; 37(1):109795. PubMed ID: 34610318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis.
    Gianotti A; Melani R; Caci E; Sondo E; Ravazzolo R; Galietta LJ; Zegarra-Moran O
    Am J Respir Cell Mol Biol; 2013 Sep; 49(3):445-52. PubMed ID: 23600628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low temperature and chemical rescue affect molecular proximity of DeltaF508-cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC).
    Qadri YJ; Cormet-Boyaka E; Rooj AK; Lee W; Parpura V; Fuller CM; Berdiev BK
    J Biol Chem; 2012 May; 287(20):16781-90. PubMed ID: 22442149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unplugging Mucus in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
    Mall MA
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S177-85. PubMed ID: 27115954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ENaC inhibitors for the treatment of cystic fibrosis.
    Butler R; Hunt T; Smith NJ
    Pharm Pat Anal; 2015 Jan; 4(1):17-27. PubMed ID: 25565157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ambroxol on chloride transport, CFTR and ENaC in cystic fibrosis airway epithelial cells.
    Varelogianni G; Hussain R; Strid H; Oliynyk I; Roomans GM; Johannesson M
    Cell Biol Int; 2013 Nov; 37(11):1149-56. PubMed ID: 23765701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment.
    Kota P
    Curr Opin Pharmacol; 2022 Jun; 64():102209. PubMed ID: 35483215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands.
    Joo NS; Irokawa T; Robbins RC; Wine JJ
    J Biol Chem; 2006 Mar; 281(11):7392-8. PubMed ID: 16410244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.